Poly(ω-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery

Biomaterials

Volumn 30, Issue 29, 2009, Pages 5707-5719

  Liu, Jie ^a,b   Jiang, Zhaozhong ^a   Zhang, Shengmin ^b   Saltzman, W Mark ^a  

^a Yale University   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antitumor effect; Camptothecin; Controlled release; Hydrophobic; Polymer nanoparticle

Indexed keywords

ANTITUMOR EFFECT; CAMPTOTHECIN; CONTROLLED RELEASE; HYDROPHOBIC; POLYMER NANOPARTICLE;

BODY FLUIDS; BUTENES; CARBOXYLATION; CELL CULTURE; CELL MEMBRANES; CHARGE TRAPPING; COPOLYMERIZATION; DRUG DELIVERY; EMULSIFICATION; ENCAPSULATION; HYDROPHOBICITY; POLYMERS; ZETA POTENTIAL;

NANOPARTICLES;

CAMPTOTHECIN; COPOLYMER; NANOPARTICLE; POLY(OMEGA PENTADECALACTONE CO BUTYLENE CO SUCCINATE); UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABILITY; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG TOLERABILITY; EMULSION; GLIOMA; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE;

ABSORBABLE IMPLANTS; ANIMALS; CAMPTOTHECIN; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; LUNG NEOPLASMS; MATERIALS TESTING; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; NANOPARTICLES; ORGAN SPECIFICITY; PARTICLE SIZE; POLYESTERS; TISSUE DISTRIBUTION;

CANDIDA ANTARCTICA;

EID: 68549136478     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.06.061     Document Type: Article

References (47)

1. Feng S.S. Nanoparticles of biodegradable polymers for new-concept chemotherapy. Expert Review of Medical Devices 1 (2004) 115-125
2. Peer D., Karp J.M., Hong S., FaroKhzad OC., Margalit R., and Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology 2 (2007) 751-760
3. Min K.H., Park K., Kim Y.S., Bae SM., Lee S., Jo HG., et al. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. Journal of Controlled Release 127 (2008) 208-218
4. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation 41 (2001) 189-207
5. Maeda H., Bharate G.Y., and Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. European Journal of Pharmaceutics and Biopharmaceutics 71 (2009) 409-419
6. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., McPhail A.T., and Sim G.A. Plant antitumor agents. I. Isolation and structure of camptothecin a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. Journal of the American Chemical Society 88 (1966) 3889-3890
7. Fassberg J., and Stella V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogs. Journal of Pharmaceutical Sciences 81 (1992) 676-684
8. Mi Z.H., and Burke T.G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33 (1994) 10325-10336
9. Hatefi A., and Amsden B. Camptothecin delivery methods. Pharmaceutical Research 19 (2002) 1389-1399
10. Creemers G.J., Lund B., and Verweij J. Topoisomerase-I inhibitors - topotecan and irenotecan. Cancer Treatment Reviews 20 (1994) 73-96
11. Pizzolato J.F., and Saltz L.B. The camptothecins. Lancet 361 (2003) 2235-2242
12. Watanabe M., Kawano K., Toma K., Hattori Y., and Maitani Y. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. Journal of Controlled Release 127 (2008) 231-238
13. Lundberg B.B. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions. Anti-Cancer Drug Design 13 (1998) 453-461
14. Eichhorn M.E., Luedemann S., Strieth S., Papyan A., Ruhstorfer H., Haas H., et al. Cationic lipid complexed camptothecin (EndoTAG((R))-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biology & Therapy 6 (2007) 920-929
15. Kawano K., Watanabe M., Yamamoto T., Yokoyama M., Opanasopit P., Okano T., et al. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. Journal of Controlled Release 112 (2006) 329-332
16. Watanabe M., Kawano K., Yokoyama M., Opanasopit P., Okano T., and Maitani Y. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. International Journal of Pharmaceutics 308 (2006) 183-189
17. Ying V., Haverstick K., Page R.L., and Saltzman W.M. Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors. Journal of Biomaterials Science - Polymer Edition 18 (2007) 1283-1299
18. Conover C.D., Greenwald R.B., Pendri A., Gilbert CW., and Shum KL. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemotherapy and Pharmacology 42 (1998) 407-414
19. Fleming A.B., Haverstick K., and Saltzman W.M. In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain. Bioconjugate Chemistry 15 (2004) 1364-1375
20. Ertl B., Platzer P., Wirth M., and Gabor F. Poly(d,l-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. Journal of Controlled Release 61 (1999) 305-317
21. Dora C.L., Alvarez-Silva M., Trentin A.G., de Faria TJ., Fernandes D., da Costa R., et al. Evaluation of antimetastatic activity and systemic toxicity of camptothecin-loaded microspheres in mice injected with B16-F10 melanoma cells. Journal of Pharmacy and Pharmaceutical Sciences 9 (2006) 22-31
22. Vasir J.K., and Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Advanced Drug Delivery Reviews 59 (2007) 718-728
23. Panyam J., and Labhasetwar V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Molecular Pharmaceutics 1 (2004) 77-84
24. Emerich D.F., Winn S.R., Snodgrass P., LaFreniere D., Agostino M., Wiens T., et al. Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors. Pharmaceutical Research 17 (2000) 776-781
25. Yang S.C., Lu L.F., Cai Y., Zhu JB., Liang BW., and Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. Journal of Controlled Release 59 (1999) 299-307
26. Kumar V., Kang J.C., and Hohl R.J. Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-cellulose microspheres prepared by spray drying. Pharmaceutical Development and Technology 6 (2001) 459-467
27. McCarron P.A., Marouf W.M., Quinn D.J., Fay F., Burden RE., Olwill SA., et al. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjugate Chemistry 19 (2008) 1561-1569
28. Kunii R., Onishi H., Ueki K.I., Koyama KI., and Machida Y. Particle characteristics and biodistribution of camptothecin-loaded PLA/(PEG-PPG-PEG) nanoparticles. Drug Delivery 15 (2008) 3-10
29. Park J., Fong P., Lu J., Russell K., Booth C., and Satzman W. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine: Nanotechnology, Biology and Medicine (2009)
30. Desai M.P., Labhasetwar V., Walter E., Levy RJ., and Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharmaceutical Research 14 (1997) 1568-1573
31. Cartiera M.S., Johnson K.M., Rajendran V., Caplan MJ., and Saltzman WM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30 (2009) 2790-2798
32. Jiang Z.Z. Lipase-catalyzed synthesis of aliphatic polyesters via copolymerization of lactone, dialkyl diester, and diol. Biomacromolecules 9 (2008) 3246-3251
33. Sano K., Yoshikawa M., Hayasaka S., Satake K., Ikegami Y., Yoshida H., et al. Simple non-ion-paired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives. Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences 795 (2003) 25-34
34. Levchenko T.S., Rammohan R., Lukyanov A.N., Whiteman KR., and Torchilin VP. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. International Journal of Pharmaceutics 240 (2002) 95-102
35. Li S.D., and Huang L. Pharmacokinetics and biodistribution of nanoparticles. Molecular Pharmaceutics 5 (2008) 496-504
36. Cu Y., and Saltzman W.M. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Molecular Pharmaceutics 6 (2009) 173-181
37. Abdelwahed W., Degobert G., Stainmesse S., and Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Advanced Drug Delivery Reviews 58 (2006) 1688-1713
38. Chacon M., Molpeceres J., Berges L., Guzman M., and Aberturas MR. Stability and freeze-drying of cyclosporine loaded poly(d,l lactide-glycolide) carriers. European Journal of Pharmaceutical Sciences 8 (1999) 99-107
39. Quintanar-Guerrero D., Ganem-Quintanar A., Allemann E., Fessi H., and Doelker E. Influence of the stabilizer coating layer on the purification and freeze-drying of poly(d,l-lactic acid) nanoparticles prepared by an emulsion-diffusion technique. Journal of Microencapsulation 15 (1998) 107-119
40. Panyam J., and Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(d,l-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharmaceutical Research 20 (2003) 212-220
41. Qaddoumi M.G., Ueda H., Yang J., Davda J., Labhasetwar V., and Lee V.H.L. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharmaceutical Research 21 (2004) 641-648
42. Prabha S., and Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharmaceutical Research 21 (2004) 354-364
43. Kobayashi K., Bouscarel B., Matsuzaki Y., Ceryak S., Kudoh S., and Fromm H. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. International Journal of Cancer 83 (1999) 491-496
44. Gao X.H., Cui Y.Y., Levenson R.M., Chung L.W.K., and Nie SM. In vivo cancer targeting and imaging with semiconductor quantum dots. Nature Biotechnology 22 (2004) 969-976
45. Wong H.L., Bendayan R., Rauth A.M., Xue HY., Babakhanian K., and Wu XY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. Journal of Pharmacology and Experimental Therapeutics 317 (2006) 1372-1381
46. Loh J.P., and Ahmed A.E. Determination of camptothecin in biological-fluids using reversed-phase high-performance liquid-chromatography with fluorescence detection. Journal of Chromatography-Biomedical Applications 530 (1990) 367-376
47. Kunii R., Onishi H., and Machida Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. European Journal of Pharmaceutics and Biopharmaceutics 67 (2007) 9-17